Conservative growth hormone/IGF-1 and mTOR signaling pathways as a target for aging and cancer prevention: Do we really have an antiaging drug?

Interdisciplinary Topics in Gerontology

Volumn 40, Issue , 2014, Pages 177-188

  Anisimov, Vladimir N ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; MTOR PROTEIN, HUMAN; SOMATOMEDIN C; TARGET OF RAPAMYCIN KINASE;

AGING; ANIMAL; HUMAN; LONGEVITY; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AGING; ANIMALS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONGEVITY; NEOPLASMS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84925970219     PISSN: 00741132     EISSN: 16623800     Source Type: Book Series    
DOI: 10.1159/000364982     Document Type: Article

References (27)

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G: The hallmarks of aging. Cell 2013; 152: 1194-1217.
2. Bnisimov VN: Carcinogenesis and aging 20 years after: escaping horizon. Mech Ageing Dev 2009; 130: 105-121.
3. Anisimov VN, Bartke A: The key role of growth hor-mone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 2013; 87:201-223.
4. Johnson SC, Rabinovitch PS, Kaeberlein M: mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493:338-345.
5. Selman C, Tullet JM, Wieser D, Irvine E, et al: Ribo-somal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326:140-144.
6. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA: Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335:1638-1643.
7. Spindler SR: Caloric restriction: from soup to nuts. Ageing Res Rev 2010; 9:324-353.
8. Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, Herbert RL, Longo DL, Allison DB, Young JE, Bryant M, Barnard D, Ward WF, Qi W, Ingram DK, de Cabo R: Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012; 489:318-321.
9. Anisimov VN, Semenchenko AV, Yashin AI: Insulin and longevity: antidiabetic biguanides as geroprotec-tors. Biogerontology 2003; 4:297-307.
10. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C: Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40:685-693.
11. Anisimov VN, Egormin PA, Piskunova TS, Popovic IG, Tyndyk ML, Yurova MV, Zabezhinski MA, Ani-kin IV, Karkach AS, Romanyukha AA: Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9: 188-197.
12. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, Se-menchenko AV: Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008; 7:2769-2773.
13. Anisimov VN, Berstein LM, Popovich IG, Zabezhin-ski MA, Tyndyk ML, Egormin PA, Piskunova TS, Yurova MN, Semenchenko AV, Kovalenko IG, Po-roshina TE: If started early in life, metformin increases life span and postpones tumors in female SHR mice. Aging (Albany) 2011; 3:148-157.
14. Anisimov VN, Piskunova TS, Popovich IG, Za-bezhinski MA, Tyndyk ML, Egormin PA, Yurova MN, Semenchenko AV, Kovalenko IG, Poroshina TE, Berstein LM: Gender differences in metformin effect on aging, life span and spontaneous tumori-genesis in 129/Sv mice. Aging (Albany) 2010; 2:945-958.
15. Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR: Metformin therapy in a transgenic mouse model of Hungtington's disease. Neurosci Lett 2007; 411:98-103.
16. Smith DL, Elam CF, Mattison JA, Lane MA, Roth GS, Ingram DK, Allison DB: Metformin supplementation and life span in Fischer-344 rats. J Gerontol Biol Sci 2010; 65A:468-474.
17. Martin-Montalvo A, Mercken EM, Mitchell SJ, Pala-cios HH, et al: Metformin improves healthspan and lifespan in mice. Nat Commun 2013; 4:2192.
18. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460:392-396.
19. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R: Rapamycin, but not resveratrol or simvastatin extend life span in genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66:191-201.
20. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV: Ra-pamycin extends maximal life span in cancer-prone mice. Am J Pathol 2010; 176:1092-2096.
21. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Yurova MN, Semenchenko AV, Tyn-dyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV: Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011; 10:4230-4236.
22. +/- mice. Aging (Albany) 2012; 4:709-717.
23. -/- mice by delaying. Aging (Albany) 2012; 4:715-722.
24. +/- mice by inhibiting neuroendocrine tumors. Aging (Albany) 2013; 5:100-110.
25. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV: Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8: 1888-1895.
26. Dilman VM: Development, Aging and Disease. A New Rationale for an Intervention. Chur, Harwood Academic Publishers, 1994.
27. Zhang G, Li J, Purkayastha S, Tang Y, Zhang H, Yin Y, Li B, Liu G, Cai D: Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature 2013;497:211-216.